Medexus Pharmaceuticals Expands Trecondyv® Access with Quebec Public Reimbursement Agreement
- Medexus Pharmaceuticals secures public reimbursement for Trecondyv® in Quebec, enhancing patient access to critical therapies.
- Trecondyv® is now publicly reimbursable in Canada’s three most populous provinces, covering approximately 75% of the population.
- The company focuses on research and development to expand its hematology-oncology portfolio and improve patient treatment access.
Medexus Pharmaceuticals Expands Access to Trecondyv® in Quebec
Medexus Pharmaceuticals Inc. achieves a significant milestone with the successful agreement for the public reimbursement of Trecondyv® (treosulfan for injection) in Quebec, Canada. The announcement, made on April 17, 2025, reveals that eligible claims for Trecondyv® will now be covered under the Public Prescription Drug Insurance Plan managed by the Régie de l'Assurance Maladie du Québec (RAMQ). This development is crucial as it allows Medexus to offer Trecondyv® to a wider patient population, enhancing access to a critical therapeutic option for patients requiring allogeneic hematopoietic stem cell transplantation.
The inclusion of Trecondyv® in Quebec's public reimbursement program follows similar arrangements in Ontario and British Columbia, allowing the treatment to be publicly reimbursable across Canada’s three most populous provinces. With approximately 75% of the Canadian population now eligible for this coverage, Medexus demonstrates its commitment to improving healthcare access for patients grappling with conditions such as acute myeloid leukemia and myelodysplastic syndromes. Richard Labelle, Medexus's Chief Operating Officer, emphasizes the company's dedication to collaborating with governmental bodies across Canada to further extend the reach of Trecondyv® and ensure that more patients can benefit from this innovative therapy.
Trecondyv® is positioned as a vital part of the preparative regimen for patients undergoing hematopoietic stem cell transplantation, especially given its documented advantages over traditional busulfan regimens. Clinical trials reveal that Trecondyv® not only results in superior outcomes but also significantly reduces non-relapse mortality rates. The data from pivotal phase 3 trials indicate that while 54.8% of patients experience treatment-emergent adverse events, only 8.5% report severe adverse reactions, suggesting a favorable safety profile. By holding exclusive commercial rights to Trecondyv® in Canada through a partnership with medac GmbH, Medexus reinforces its role as a leader in providing innovative hematology-oncology therapies.
In addition to the reimbursement agreement, Medexus Pharmaceuticals continues to prioritize research and development, focusing on expanding its hematology-oncology portfolio. The company actively seeks opportunities to collaborate with healthcare organizations to optimize patient access to treatment options. This strategic approach aligns with Medexus's broader mission of delivering effective therapies that cater to the unique needs of patients battling complex diseases.
Overall, the successful public reimbursement of Trecondyv® in Quebec marks a pivotal advancement for Medexus Pharmaceuticals, positioning the company as a key player in the Canadian healthcare landscape while providing hope for patients in need of advanced treatment for serious hematological conditions.